Early infantile epileptic encephalopathies …

Jules C Beal MD

Epilepsy & Seizures

Updated 11.08.2023
Released 10.18.1993
Expires For CME 11.08.2026

Early infantile epileptic encephalopathies

Author: Jules C Beal MD

See Contributor Disclosures

Editor: Solomon L Moshé MD

Early infantile epileptic encephalopathies

In This Article

Quick Link

Introduction

Overview

Early infantile epileptic encephalopathy (EIEE) is an epileptic encephalopathy syndrome with onset either in the neonatal period or within the first 3 months of life. It is characterized by a variety of seizure semiologies and characteristic EEG findings. The prognosis is severe. Distinct syndromes have been described, including early myoclonic encephalopathy and Ohtahara syndrome. However, there is considerable clinical overlap between them, and they may be considered a continuum of disease rather than distinct entities. In this article, the clinical, genetic, neurophysiologic, and etiologic data related to early infantile epileptic encephalopathy are reviewed.

Key points

	• Early infantile epileptic encephalopathy is an epileptic syndrome with onset either in the neonatal period or within the first 3 months of life.
	• The syndrome is clinically characterized by tonic spasms, myoclonus, or focal seizures and a suppression-burst pattern on EEG.
	• Early infantile epileptic encephalopathy is believed to have various etiologies; genetic abnormalities, structural lesions, and metabolic disorders have all been implicated, or the etiology may remain unknown.
	• Prognosis is poor.

Historical note and terminology

Ohtahara syndrome and neonatal myoclonic encephalopathy were initially described as separate clinical entities in the 1970s (54; 02), and they continued to be classified that way for many years.

In the 1989 revised classification by the International League Against Epilepsy, these conditions remained distinct, and both were classified under "symptomatic generalized epilepsies and syndromes with non-specific etiology" (13). In 2001, the International League Against Epilepsy proposed to include both syndromes under the category of epileptic encephalopathies, conditions in which not only the epileptic activity but also the epileptiform EEG abnormalities themselves are believed to contribute to the progressive disturbance in cerebral function (21). In 2010, the proposed organization presented by the Classification Commission of the International League Against Epilepsy included both Ohtahara syndrome and early myoclonic encephalopathy as “electroclinical syndromes” distinguished by clinical and EEG characteristics (08).

Throughout this time, the term “early infantile epileptic encephalopathy” was also used in clinical practice, referring to a spectrum of epileptic encephalopathy syndromes occurring during infancy. In 2022 the International League Against Epilepsy Task Force on Nosology and Definitions recommended that the term “early infantile developmental and epileptic encephalopathy” be used for all of these conditions (66), noting that distinguishing between Ohtahara syndrome and early myoclonic encephalopathy “no longer provides valuable information for clinical decision-making or determination of prognosis” (68).

Clinical manifestations

Presentation and course

	• Seizure types include tonic seizures, myoclonic seizures, and epileptic spasms.
	• Cognitive and developmental disabilities are typical.
	• Interictal EEG often shows a suppression burst pattern, multifocal discharges, or diffuse slowing.

Seizures typically occur within the first 3 months of life, often in the first weeks and sometimes as early as a few hours after birth (53; 11). Tonic seizures are common. They may be either generalized and symmetrical or lateralized and occur during both wakefulness and during sleep. The seizures are very frequent, with affected patients experiencing as many as 100 to 300 isolated seizures or 10 to 20 clusters of seizures per day (55).

Myoclonic seizures are also common and, in some patients, may be the predominant seizure type. The myoclonus usually involves the face or extremities and may be restricted to an eyebrow, a single limb, or a finger, or it may be bilateral. The jerks occur when infants are awake or asleep, and they are often described as "erratic" because they can shift from one part of the body to another in a random, asynchronous fashion. Frequency varies from occasional to almost continuous.

Focal motor seizures can be present as well. In some patients, there may be subtle focal seizures involving, for example, eye deviation or autonomic phenomena, such as apnea or flushing of the face (14). Sequential seizures may be present, involving several different seizure semiologies occurring in sequence as part of a single seizure event (58).

Neurologic abnormalities are nearly universal, including very severe delays in psychomotor acquisitions, marked hypotonia, and disturbed alertness. Dalla Bernardina and colleagues reported deterioration in their patients (14); this characteristic is difficult to confirm because the onset of the disease is very early. Movement disorders may be seen, including chorea, tremor, and dystonia (68). Status dystonicus has been described (25).

The EEG in early infantile epileptic encephalopathy is abnormal. A suppression burst pattern is commonly seen, consisting of spikes, sharp waves, and slow waves, which are irregularly intermingled and separated by periods of electrical suppression. The burst-suppression pattern is not always found at seizure onset, and repetition of EEG may be necessary to demonstrate the presence of this pattern (57). Other abnormalities include multifocal epileptiform discharges, diffuse slowing, and discontinuity (68). There is no normal background activity (01).

Prognosis and complications

The clinical progression of this condition is marked by severe psychomotor retardation, and death in infancy is common and often attributed to pneumonia/respiratory illness or sudden unexpected death in epilepsy (SUDEP). Those who survive are typically mentally and physically handicapped, even among those in whom seizures are eventually relatively well controlled (31).

In some cases, the epilepsy may evolve into focal epilepsy or into infantile epileptic spasms syndrome over time; some of these patients may subsequently evolve to Lennox-Gastaut syndrome.

Clinical vignette

After a normal pregnancy, this first-born son of nonconsanguineous parents was delivered by cesarean section because the umbilical cord was wrapped around the neck. On about the 10th day of life, the parents noticed myoclonic jerks involving the face and body.

The child was hospitalized at the age of 45 days. On examination, he was hypotonic with decreased reactivity; localized and segmentary myoclonic jerks, sometimes massive, were observed. The EEG showed a suppression burst pattern during sleep and while awake; the bursts lasted 7 to 8 seconds, appeared sometimes synchronously and sometimes asynchronously over the two hemispheres, and consisted of discharges of slow waves overlapped by spikes and fast activity. The suppression phases lasted 10 to 15 seconds.

During EEG recording, 100 mg pyridoxine administered intravenously failed to modify the EEG pattern.

Results of MRI, performed also with spectroscopy, were normal. Blood samples tested for amino acids, lactate, ammonia, and very-long-chain fatty acids were normal. Urine tested for urinary organic acids and purines was normal. The glycorrhachia/glycemia ratio was within normal range. Sulfite test was negative, thus, excluding molybdenum cofactor deficiency.

The child was treated with folic acid 5 mg/day without improvement. Vigabatrin 100 mg/kg per day did not control the seizures, after which clonazepam 1 mg/kg per day was added, but still without results. At about 3 months of age, tonic spasms appeared.

In the following months, the child continued to be hypotonic, nonreactive, and lethargic, sometimes with poor distinction between waking and sleep. Myoclonic manifestations and tonic spasms persisted. Clonazepam was discontinued at 4 months of age. At age 6 months, the seizures suddenly stopped spontaneously. The child seemed to react slightly more to stimulation. The EEG showed progressive regression of burst-suppression pattern that was replaced by diffuse nearly continuous epileptiform abnormalities, which were more prevalent in the frontal regions and more evident during sleep.

At age 18 months, repeat MRI showed mild dilatation of lateral ventricles and cortical spaces; new metabolic screening failed to show any alteration.

At age 2 years, the child showed very severe cognitive impairment. He occasionally tracked and started to smile, but he could not control his head or trunk and did not make any voluntary movement. Diffuse hypertonicity was present. He occasionally had segmentary or massive myoclonic jerks. The EEG showed slow, disorganized brain activity and many multifocal and diffuse epileptiform abnormalities.

Biological basis

	• Early infantile epileptic encephalopathy is associated with a variety of underlying etiologies.
	• Structural lesions, genetic abnormalities, and metabolic disorders have all been implicated.
	• There may be a “final common pathway” whereby multiple underlying disorders can lead to the same pathologic abnormalities or phenotypic syndrome.

Etiology and pathogenesis

Early infantile epileptic encephalopathy is believed to have various possible underlying etiologies that often remain unknown, ultimately resulting in a diffuse process that likely involves the brainstem and white matter and possibly leads to deafferentation and hyperexcitability of the cortex (06). Because of the close relationship between early infantile epileptic encephalopathy, infantile epileptic spasms syndrome, and Lennox-Gastaut syndrome, it is suggested that these all represent age-specific responses of the brain at various developmental stages to heterogeneous, nonspecific exogenous factors (53).

Pathology. Associated structural brain abnormalities include agenesis or dysgenesis of the corpus callosum, dentato-olivary dysplasia, cerebellar hypoplasia, pontine hypoplasia, delayed or abnormal myelination, cerebral atrophy, focal polymicrogyria, and ventriculomegaly (11; 56; 43; 59; 35). There is a strong association between early infantile epileptic encephalopathy and hemimegalencephaly (23). Several studies discuss the role of cortical dysgenesis in relation to the early infantile encephalopathies (60).

Metabolic disorders are also common. Numerous cases have been associated with nonketotic hyperglycinemia (11; 45; 07). Pyridoxine dependency and pyridox(am)ine-5-phosphate oxidase deficiency must also be considered (65; 27; 56). Other metabolic disorders have been reported, including D-glyceric acidemia (26), propionic acidemia (45), molybdenum cofactor deficiency (31), carnitine palmitoyltransferase deficiency (23), glycosylation disorders (09), and methylmalonic acidemia (45).

Pathologic findings reported in early infantile epileptic encephalopathy include a drop-out of cortical neurons and astrocytic proliferation, severe multifocal spongy changes in the white matter, perivascular concentric bodies, demyelination in cerebral hemispheres, imperfect lamination of the deeper cortical layers, and unilateral enlargement of cerebral hemisphere with astrocytic proliferation (01).

Spreafico and colleagues reported that the presence of numerous large spiny neurons dispersed in the white matter along the axons of the cortical gyri is common; this has been interpreted as an abnormal persistence of interstitial cells (60).

Reviewing published autopsy cases, Djukic and colleagues found that brainstem and cerebellar abnormalities were consistently present (17; 18). It is possible that the prominence of tonic seizures in early infantile epileptic encephalopathy may be an indication of brainstem dysfunction. It has been shown that the bursts in the suppression burst EEG pattern may be associated with the brainstem, thalamus, and cortex and the periods of suppression only with the cortex, suggesting a deafferentation between cortical and subcortical structures (34). Of note, brainstem dysfunction is also thought to contribute to the development of hypsarrhythmia in infantile spasms (42) and may play a role in the transition from early infantile epileptic encephalopathy to infantile epileptic spasms syndrome.

Genetics. Genetic mutations have been increasingly recognized in early infantile epileptic encephalopathy. Common genetic abnormalities involve pathogenic variants in KCNQ2, SCN2A, STXBP1, CDKL5, ARX, and SCN8A (56; 43; 48; 62; 68; 35).

Less commonly reported genetic abnormalities include mutations in AMT (07), AARS, ARX (05), ALG13 (09), BRAT1, CASK (43), CYFIP2 (15), DMXL2 (22), DEPDC5 (43), DOCK7 (39), ErbB4 (04), GABRA1, GABRB2 (32), GNAO1 (30), KCNT1 (25), KCNT2, NECAP1, PACS2 (10), PNPO (27; 31), PIGA, PIGQ (56), RARS2 (67), SCN1A (33), SEPSECS (56), SETBP1 (05), SIK1 (30), SLC25A22 (12), TBC1D24, UDGH (35), UBA5 (46), and VOUS (43). Nicita and colleagues reported a patient with a genetic deletion encompassing the STXBP1, SPTAN1, ENG, and TOR1A genes (52). Aravindhan and colleagues reported a patient with a deletion involving STXBP1 and SPTAN1 (03).

In some cases, genetic abnormalities have been associated with specific phenotypic features. For example, UBA5 is predominantly associated with myoclonic seizures (68). Mutations in SCN8A tend to be associated with focal seizures (24). KCNT1 mutations may present with focal tonic seizures with autonomic symptoms (20). Mutations involving SCN2A, STXBP1, and CDKL5 are associated with tonic seizures or sequential seizures (47; 20; 68).

Diagnostic workup

	• EEG is a key test in confirming the clinical diagnosis.
	• Follow-up testing, including brain imaging, metabolic testing, and genetic testing, can help to identify underlying etiologies and may help guide treatment.

The EEG is often characterized by a suppression burst pattern with bursts of spikes, sharp waves, and slow waves, which are irregularly intermingled and separated by periods of electrical attenuation. The pattern can be widespread and synchronous, asynchronous over both hemispheres, or limited to one side. Other abnormal findings may include multifocal spikes, discontinuity, and diffuse slowing (68). There is no normal background activity (01). High-frequency EEG activity in the range of 80 to 150 Hz has been associated with the bursts (63). The suppression burst pattern is not always found at seizure onset (57). It can evolve into hypsarrhythmia or into multifocal paroxysms in some cases.

On imaging, CT and MRI may reveal specific findings consistent with the malformative etiologies previously described, including hemimegalencephaly, agenesis or dysgenesis of the corpus callosum, dentato-olivary dysplasia, cerebellar hypoplasia, pontine hypoplasia, and cerebral atrophy, among others. In some cases, the brain may be grossly normal (01).

Testing for metabolic disorders should be performed, including nonketotic hyperglycinemia, pyridoxine dependency, and pyridox(am)ine-5-phosphate oxidase deficiency. Screening with serum amino acid and urine organic acid testing is recommended. Genetic testing may reveal abnormalities and is recommended.

Genetic testing may be revealing. A multicenter international study suggested that rapid genome sequencing in infants with new-onset epilepsy is feasible and may have implications for treatment and prognosis (16).

Management

	• No definitive treatment exists.
	• Treatment with antiseizure medications yields inconsistent results.
	• Treatments may be available for individuals with recognized metabolic disorders, though it is unclear whether these improve long-term outcomes.

Drug treatment. Evidence for the use of specific antiseizure medications in early infantile epileptic encephalopathy is anecdotal. Phenobarbital, valproate, pyridoxine, zonisamide, topiramate, levetiracetam, and benzodiazepines have been used with limited effectiveness to control seizures (43; 49). Sodium channel agents were reported to control seizures in several patients with mutations in SCN1A and KCNQ2, but this did not improve long-term outcome (51; 38; 50). Sodium channel agents similarly had inconsistent effects in patients with SCN8A mutations (29). Kosaka and colleagues reported an infant who had a significant seizure reduction on high-dose phenobarbital (serum levels between 50 and 60 microgram/milliliter) (41). Ishikawa and colleagues reported a patient with an SCN1A mutation who had a reduction in seizures on perampanel (33). Adrenocorticotropic hormone therapy has also had limited efficacy and may be beneficial in cases that progress to infantile epileptic spasms syndrome (55; 37). The ketogenic diet has been reported to have a beneficial effect in some cases (11; 38; 09). No medications are effective in treating the developmental disability and progressive decline that are typical of this condition.

Metabolic treatments. Cases in which a metabolic disorder is identified and corrected may have a better outcome and improved psychomotor development. A trial of pyridoxine is always justified (65). Supplementation of pyridoxal 5′-phosphate can lead to substantial improvements in patients with pyridox(am)ine-5′-phosphate oxidase (PNPO) deficiency (27). Folinic acid was reported to dramatically reduce seizures and improve the EEG in a patient with STXBP1 mutation (64).

In nonketotic hyperglycinemia, pyridoxine and benzoate can normalize the levels of glycine in the blood and improve the EEG picture, but without improvements in prognosis. There have been several reported cases of a reduction in seizure frequency using the ketogenic diet in individuals with nonketotic hyperglycinemia (36).

Surgery. Cases with hemimegalencephaly or cortical dysplasia can benefit from neurosurgical treatment with hemispherectomy or focal resection (40), or possibly disconnection surgery (44). Vagus nerve stimulation has been reported to benefit some patients (19). Appropriately chosen patients who are treated surgically may have a favorable outcome in terms of seizure control and development (28).

Outcomes

Prognosis is generally poor. Mortality is high in the first 2 years of life. The seizures are often intractable to currently available antiepileptic therapy. Severe psychomotor retardation is almost universal in survivors, even among those in whom seizures are eventually relatively well controlled (31). Correction of underlying genetic and metabolic disorders, if identified, can improve prognosis.

References

01: Aicardi J. Early myoclonic encephalopathy. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey Eurotext, 1985.
02: Aicardi J, Goutieres F. Encephalopathie myoclonique neonatale. Rev EEG Neurophysiol 1978;8:99-101. PMID 663355
03: Aravindhan A, Shah K, Pak J, Veerapandiyan A. Early-onset epileptic encephalopathy with myoclonic seizures related to 9q33.3-q34.11 deletion involving STXBP1 and SPTAN1 genes. Epileptic Disord 2018;20(3):214-8. PMID 29897043
04: Backx L, Ceulemans B, Vermeesch JR, Devriendt K, Van Esch H. Early myoclonic encephalopathy caused by a disruption of the neuregulin-1 receptor ErbB4. Eur J Hum Genet 2009;17:378-82. PMID 18854870
05: Bayat A, Bayat M, Rubboli G, Møller RS. Epilepsy syndromes in the first year of life and usefulness of genetic testing for precision therapy. Genes (Basel) 2021;12(7):1051. PMID 34356067
06: Beal JC, Cherian KA, Moshé SL. The early onset epileptic encephalopathies: Ohtahara syndrome and early myoclonic encephalopathy. Pediatr Neurol 2012;47(5):317-23. PMID 23044011
07: Belcastro V, Barbarini M, Barca S, Mauro I. A novel AMT gene mutation in a newborn with nonketotic hyperglycinemia and early myoclonic encephalopathy. Eur J Paediatr Neurol 2016;20(1):192-5. PMID 26371980
08: Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51:676-85. PMID 20196795
09: Chand P, Sulaiman A, Angez M, Kirmani S. Early infantile epileptic encephalopathy in asparagine-linked glycosylation thirteen (ALG13) gene defect and dramatic response with ketogenic diet. J Pak Med Assoc 2023;73(7):1521-3. PMID 37469072
10: Chou IJ, Hou JY, Fan WL, Tsai MH, Lin KL. Long-term outcome of neonatal seizure with PACS2 mutation: case series and literature review. Children (Basel) 2023;10(4):621. PMID 37189870
11: Clarke M, Gill J, Noronha M, McKinlay I. Early infantile epileptic encephalopathy with suppression burst: Ohtahara syndrome. Dev Med Child Neurol 1987;29(4):520-8. PMID 3678631
12: Cohen R, Basel-Vanagaite L, Goldberg-Stern H, et al. Two siblings with early infantile myoclonic encephalopathy due to mutation in the gene encoding mitochondrial glutamate/H+ symporter SLC25A22. Eur J Paediatr Neurol 2014;18(6):801-5. PMID 25033742
13: Commission of Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99. PMID 2502382
14: Dalla Bernardina B, Dulac O, Fejerman N, et al. Early myoclonic epileptic encephalopathy (E.M.E.E.). Eur J Pediatr 1983;140:248-52. PMID 6414818
15: Da Silva Cardoso J, Gomes R, Abreu M, Parente Freixo J, Falcão Reis C, Garrido C. Clinical role of codon 87 of the CYFIP2 gene in early infantile epileptic encephalopathy: a clinical case description. Cureus 2023;15(2):e35323. PMID 36968925
16: D'Gama AM, Mulhern S, Sheidley BR, et al. Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study. Lancet Neurol 2023;22(9):812-25. PMID 37596007
17: Djukic A, Lado FA, Shinnar S, Moshe SL. Are early myoclonic encephalopathy (EME) and the Ohtahara syndrome (EIEE) independent of each other. Epilepsy Res 2006;70:68-76. PMID 16829044
18: Djukic A, Vigevano F, Plouin P, Moshe SL. Early myoclonic encephalopathy (neonatal myoclonic encephalopathy). In: Engel J, Pedley TA, editors. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008:2297-301.
19: Dong M, Zhang T, Hu R, Li M, Wang G, Liu X. Genotype and phenotype spectrum of 10 children with STXBP1 gene-related encephalopathy and epilepsy. Front Pediatr 2022;10:1010886. PMID 36440324
20: El Kosseifi C, Cornet MC, Cilio MR. Neonatal developmental and epileptic encephalopathies. Semin Pediatr Neurol 2019;32:100770. PMID 31813518
21: Engel J Jr; International League Against Epilepsy. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42(6):796-803. PMID 11422340
22: Esposito A, Falace A, Wagner M, et al. Biallelic DMXL2 mutations impair autophagy and cause Ohtahara syndrome with progressive course. Brain 2019;142(12):3876-91. PMID 31688942
23: Fusco L, Pachatz C, Di Capua M, Vigevano F. Video/EEG aspects of early-infantile epileptic encephalopathy with suppression-bursts (Ohtahara syndrome). Brain Dev 2001;23(7):708-14. PMID 11701283
24: Gardella E, Marini C, Trivisano M, et al. The phenotype of SCN8A developmental and epileptic encephalopathy. Neurology 2018; Sep 18;91(12):e1112-24. PMID 30171078
25: Gertler TS, Thompson CH, Vanoye CG, Millichap JJ, George AL Jr. Functional consequences of a KCNT1 variant associated with status dystonicus and early-onset infantile encephalopathy. Ann Clin Transl Neurol 2019;6(9):1606-15. PMID 31560846
26: Grandgeorge D, Favier A, Bost M, et al. L'acidimie D-glycirique. A propos d'une nouvelle observation anatomo-clinique. Arch Franc Pediatr 1980;37:577-84.
27: Guerin A, Aziz AS, Mutch C, Lewis J, Go CY, Mercimek-Mahmutoglu S. Pyridox(am)ine-5-phosphate oxidase deficiency treatable cause of neonatal epileptic encephalopathy with burst suppression: case report and review of the literature. J Child Neurol 2015;30(9):1218-25. PMID 25296925
28: Guerrero Ruiz GDP. Epileptic encephalopathies of onset in neonates and infants. [Article in Spanish] Medicina (B Aires) 2022;82 Suppl 3:13-8. PMID 36054851
29: Guo QB, Zhan L, Xu HY, Gao ZB, Zheng YM. SCN8A epileptic encephalopathy mutations display a gain-of-function phenotype and divergent sensitivity to antiepileptic drugs. Acta Pharmacol Sin 2022;43(12):3139-48. PMID 35902765
30: Hansen J, Snow C, Tuttle E, et al. De novo mutations in SIK1 cause a spectrum of developmental epilepsies. Am J Hum Genet 2015;96(4):682-90. PMID 25839329
31: Howell KB, Freeman JL, Mackay MT, et al. The severe epilepsy syndromes of infancy: a population-based study. Epilepsia 2021;62(2):358-70. PMID 33475165
32: Ishii A, Kang JQ, Schornak CC, et al. A de novo missense mutation of GABRB2 causes early myoclonic encephalopathy. J Med Genet 2017;54(3):202-11. PMID 27789573
33: Ishikawa N, Tateishi Y, Tani H, et al. Successful treatment of intractable life-threatening seizures with perampanel in the first case of early myoclonic encephalopathy with a novel de novo SCN1A mutation. Seizure 2019;71:20-3. PMID 31176277
34: Japaridze N, Muthuraman M, Reinicke C, et al. Neuronal networks during burst suppression as revealed by source analysis. PLoS One 2015;10(4):e0123807. PMID 25927439
35: Jiang L, Bi S, Lin L, He F, Deng F. Phenotypic and genetic characteristics of 24 cases of early infantile epileptic encephalopathy in East China, including a rare case of biallelic UGDH mutations. Mol Genet Genomic Med 2023;11(2):e2269. PMID 37593999
36: Kava MP, Robertson A, Greed L, Balasubramaniam S. Ketogenic diet, a potentially valuable therapeutic option for the management of refractory epilepsy in classical neonatal nonketotic hyperglycinemia: a case report. Eur J Clin Nutr 2019;73(6):961-5. PMID 30108280
37: Kim HJ, Yang D, Kim SH, et al. Clinical characteristics of KCNQ2 encephalopathy. Brain Dev 2021;43(2):244-50. PMID 32917465
38: Kim HJ, Yang D, Kim SH, et al. The phenotype and treatment of SCN2A-related developmental and epileptic encephalopathy. Epileptic Disord 2020;22(5):563-70. PMID 33000761
39: Kivrak Pfiffner F, Koller S, Ménétrey A, et al. Homozygosity for a novel DOCK7 variant due to segmental uniparental isodisomy of chromosome 1 associated with early infantile epileptic encephalopathy (EIEE) and cortical visual impairment. Int J Mol Sci 2022;23(13):7382. PMID 35806387
40: Komaki H, Sugai K, Sasaki K, et al. Surgical treatment of a case of early infantile epileptic encephalopathy with suppression-bursts associated with focal cortical dysplasia. Epilepsia 1999;40(3):365-9. PMID 10080520
41: Kosaka T, Ohta G, Kometani H, Kawatani M, Ohshima Y. A case of early myoclonic encephalopathy with intractable seizures successfully treated with high-dose phenobarbital. Brain Dev 2019;41(8):717-20. PMID 31027651
42: Lado FA, Moshe SL. Role of subcortical structures in the pathogenesis of infantile spasms: what are possible subcortical mediators. Int Rev Neurobiol 2002;49:115-40. PMID 12040889
43: Lee S, Kim SH, Kim B, et al. Genetic diagnosis and clinical characteristics by etiological classification in early-onset epileptic encephalopathy with burst suppression pattern. Epilepsy Res 2020;163:106323. PMID 32247221
44: Lee WC, Chen HH, Yang TF, et al. Early surgery for Ohtahara syndrome associated with cortical dysplasia. Pediatr Neurol 2023;148:28-31. PMID 37651974
45: Lombroso C. Early myoclonic encephalopathy, early infantile epileptic encephalopathy and benign and severe infantile myoclonic epilepsies: a critical review and personal contributions. J Clin Neurophysiol 1990;7:380-408. PMID 2120281
46: Mignon-Ravix C, Milh M, Kaiser CS, et al. Abnormal function of the UBA5 protein in a case of early developmental and epileptic encephalopathy with suppression-burst. Hum Mutat 2018;39(7):934-8. PMID 29663568
47: Milh M, Villeneuve N, Chouchane M, et al. Epileptic and nonepileptic features in patients with early onset epileptic encephalopathy and STXBP1 mutations. Epilepsia 2011;52(10):1828-34. PMID 21770924
48: Mitta N, Menon RN, McTague A, et al. Genotype-phenotype correlates of infantile-onset developmental & epileptic encephalopathy syndromes in South India: a single centre experience. Epilepsy Res 2020;166:106398. PMID 32593896
49: Moon JU, Cho KO. Current pharmacologic strategies for treatment of intractable epilepsy in children. Int Neurourol J 2021;25(Suppl 1):S8-18. PMID 34053206
50: Najera Chavez BC, Seeber L, Goldhahn K, Panzer A. Use of sodium channel blockers in the Thr226Met pathologic variant of SCN1A: a Case report. Neuropediatrics 2023;54(6):417-21. PMID 37467773
51: Nakano K, Kobayashi K, Maniwa S, Kodani N, Ohtsuka Y. Successful treatment of early myoclonic encephalopathy using lidocaine and carbamazepine. Epileptic Disord 2013;15(3):352-7. PMID 23886871
52: Nicita F, Ulgiati F, Bernardini L, et al. Early myoclonic encephalopathy in 9q33-q34 deletion encompassing STXBP1 and SPTAN1. Ann Hum Genet 2015;79(3):209-17. PMID 25779878
53: Ohtahara S. Seizure disorders in infancy and childhood. Brain Dev 1984;6(6):509-19. PMID 6534199
54: Ohtahara S, Ishida T, Oka E, Yamatogy Y, Inoue H. On the specific age-dependent epileptic syndromes: the early-infantile epileptic encephalopathy with suppression-burst. No To Hattatsu 1976;8:270-80.
55: Ohtahara S, Yamatogi Y. Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy. Epilepsy Res 2006;70 Suppl 1:S58-67. PMID 16829045
56: Olson HE, Kelly M, LaCoursiere CM, et al. Genetics and genotype-phenotype correlations in early onset epileptic encephalopathy with burst suppression. Ann Neurol 2017;81(3):419-29. PMID 28133863
57: Ozyurek H, Turanli G, Aliefendioglu D, Coskun T. Repetitive EEG recordings are necessary for the diagnosis of early myoclonic encephalopathy. Neurol India 2005;53:235-7. PMID 16010070
58: Pressler RM, Cilio MR, Mizrahi EM, et al. The ILAE classification of seizures and the epilepsies: modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia 2021;62(3):615-28. PMID 33522601
59: Sekar S, Rudrabhatla P, Selvadasan V, Thomas B, Kesavadas C. Teaching NeuroImages: Ohtahara syndrome due to unilateral perisylvian polymicrogyria. Neurology 2021;96(19):e2456-7. PMID 33402442
60: Spreafico R, Angelini L, Binelli S, et al. Burst suppression and impairment of neocortical ontogenesis: electroclinical and neuropathologic findings in two infants with early myoclonic encephalopathy. Epilepsia 1993;34(5):800-8. PMID 8404728
61: Symonds JD, Elliot KS, Shetty J, et al. Early childhood epilepsies: epidemiology, classification, aetiology, and socio-economic determinants. Brain 2021;144:2879-91. PMID 34687210
62: Takeda K, Miyamoto Y, Yamamoto H, Ishii A, Hirose S, Yamamoto H. Clinical features of early myoclonic encephalopathy caused by a CDKL5 mutation. Brain Dev 2020;42(1):73-6. PMID 31492455
63: Toda Y, Kobayashi K, Hayashi Y, et al. High-frequency EEG activity in epileptic encephalopathy with suppression-burst. Brain Dev 2015;37(2):230-6. PMID 24796721
64: Tso WWY, Kwong AKY, Fung CW, Wong VCN. Folinic acid responsive epilepsy in Ohtahara syndrome caused by STXBP1 mutation. Pediatr Neurol 2014;50(2):177-80. PMID 24315539
65: Vigevano F, Bartuli A. Infantile epileptic syndromes and metabolic etiologies. J Child Neurol 2002;17 Suppl 3:3S9-13. PMID 12597051
66: Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: report of the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1333-48. PMID 35503715
67: Xu Y, Wu BB, Wang HJ, Zhou SZ, Cheng GQ, Zhou YF. A term neonate with early myoclonic encephalopathy caused by RARS2 gene variants: a case report. Transl Pediatr 2020;9(5):707-12. PMID 33209735
68: Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1349-97. PMID 33503712

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Jules C Beal MD

Dr. Beal of Weill Cornell Medicine and New York-Presbyterian Queens Hospital has no relevant financial relationships to disclose.
See Profile

Editor

Solomon L Moshé MD

Dr. Moshé of Albert Einstein College of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Solomon L Moshé MD
Jerome Engel Jr MD PhD
Fritz Dreifuss MD (original author), Federico Vigevano MD, Koshi A Cherian MD

Patient Profile

Age range of presentation: 0 to 23 months
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Generalized convulsive epilepsy, with intractable epilepsy: 345.11

Lack of expected normal physiological development in childhood: 783.4
ICD-10: Generalized idiopathic epilepsy and epileptic syndromes: G40.3

Lack of expected normal physiological development, unspecified: R62.9

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Early infantile epileptic encephalopathies

Associated Disorders

Epileptic encephalopathies
Symptomatic generalized epilepsy

Differential Diagnosis

Ohtahara syndrome
neonatal convulsion
hypoxic ischemic encephalopathy

Also Relevant

Benign sleep myoclonus of infancy
Benign nonepileptic infantile spasms
Epilepsy
Epileptic spasms
Generalized onset tonic seizures
- Lennox-Gastaut syndrome
- West syndrome

Clinical Categories

Epilepsy & Seizures

Patient Handouts

Ohtahara syndrome

Web References

Guidelines

Early infantile epileptic encephalopathies …

Early infantile epileptic encephalopathies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

Early infantile epileptic encephalopathies

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Anti-LGI1 encephalitis

Self-limited (familial) neonatal epilepsy

Epilepsy with auditory features

Alcohol withdrawal seizures

Epileptic lesions due to malformation of cortical development

Epileptic spasms

Sleep and epilepsy

Neocortical temporal lobe seizures

This is an article preview.
Start a Free Account
to access the full version.